Capecitabine in colorectal cancer

Capecitabine is an oral pro-drug that is converted, via a three-step enzymatic pathway, into the cytotoxic drug 5-fluorouracil. 5-fluorouracil has an established role in the management of patients with colorectal cancer in the adjuvant and advanced disease settings. In this article we review the ava...

Full description

Saved in:
Bibliographic Details
Published inClinical practice (London, England) Vol. 6; no. 2; pp. 239 - 248
Main Authors Braun, Michael S, Twelves, Chris J
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.03.2009
Subjects
5FU
capecitabine
Colorectal cancer
combination chemotherapy
oral chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Capecitabine is an oral pro-drug that is converted, via a three-step enzymatic pathway, into the cytotoxic drug 5-fluorouracil. 5-fluorouracil has an established role in the management of patients with colorectal cancer in the adjuvant and advanced disease settings. In this article we review the available clinical data for the use of capecitabine as a single agent or in combination with other cytotoxic drugs (e.g., irinotecan or oxaliplatin), or targeted anticancer treatment (e.g., anti-EGF receptor or VEGF therapy), in patients with early-stage or advanced colorectal cancer.
ISSN:1475-0708
2044-9038
1744-831X
2044-9046
DOI:10.2217/14750708.6.2.239